# US 2003/0228622 A1 · Lanthanide binding tags

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228622 A1
- Document ID: US20030228622A1
- Status: Published application
- Kind: A1
- Application number: 10/235,561
- Filed: 2002-09-05
- Published: 2003-12-11
- Earliest claimed: 2001-09-07
- Assignees: Massachusetts Institute of Technology; Trustees of Boston University
- Inventors: Barbara Imperiali; Karen N. Allen; Katherine J. Franz
- Web page: https://patentgrep.com/patent/US20030228622A1

## CPC

- C12N 15/62: DNA sequences coding for fusion proteins
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/582: {with fluorescent label}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- Y10S 435/968: High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides lanthanide binding tags (LBT) that selectively complex trivalent lanthanide (Ln) ions and afford stable complexes with desirable physical properties, including at least one of fluorescence and anomalous x-ray scattering.

## Claims

### Claim 1

A method of determining the structure of a peptide, comprising:
a) expressing a fusion peptide comprising the peptide and a lanthanide binding tag;
b) isolating said fusion peptide; and
c) forming a crystal of said fusion peptide in the presence of a lanthanide ion;
wherein the lanthanide binding tag is a peptide that contains: (a) about 12 to about 30 amino acid residues, (b) at least two carboxylic groups and (c) at least one oxygen containing group selected from the group consisting of an backbone carbonyl group, the carboxyl terminus, Ser, Thr, Gln, Asn, or an oxygen of a bound solvent molecule and
wherein the lanthanide binding tag binds a lanthanide ion with an affinity (KD) of about 1 nM to about 10 μM.

### Claim 2 (depends on 1)

The method of claim 1, further comprising determining the two-dimensional or three-dimensional crystal structure of the protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein determining is performed by x-ray crystallography.

### Claim 4 (depends on 2)

The method of claim 2, wherein determining is performed by electron microscopy.

### Claim 5

A method of detecting a peptide comprising:
a) contacting a sample containing a fusion peptide comprising the peptide and a lanthanide binding tag with a lanthanide ion;
b) determining the fluorescence of the sample;
wherein the lanthanide binding tag is a peptide that contains: (a) about 12 to about 30 amino acid residues, (b) at least two carboxylic groups, (c) a fluorophore, and (d) at least one oxygen containing group selected from the group consisting of an backbone carbonyl group, the carboxyl terminus, Ser, Thr, Gln, Asn, or an oxygen of a bound solvent molecule and
wherein the lanthanide binding tag binds a lanthanide ion with an affinity (KD) of about 1 nM to about 10 μM.

### Claim 6 (depends on 5)

The method of claim 5, further comprising c) quantitating the amount of fluorescence of the sample.

### Claim 7 (depends on 5)

The method of claim 5, wherein the sample contains a competing ligand which binds in place of the fusion peptide and which alters fluorescence upon binding.

### Claim 8 (depends on 7)

The method of claim 7, wherein the fluorescence is altered by about ±5% or more.

### Claim 9 (depends on 8)

The method of claim 8, further comprising determining the binding affinity of the ligand to the second peptide.

### Claim 10

A method of imaging, comprising:
a) injecting a solution containing a complex of a lanthanide ion and a fusion peptide comprising a peptide and a lanthanide binding tag into a patient;
b) performing imaging on said patient;
wherein the lanthanide binding tag is a peptide that contains: (a) about 12 to about 30 amino acid residues, (b) at least two carboxylic groups and (c) at least one oxygen containing group selected from the group consisting of an backbone carbonyl group, the carboxyl terminus, Ser, Thr, Gln, Asn, or an oxygen of a bound solvent molecule and
wherein the lanthanide binding tag binds the lanthanide ion with an affinity (KD) of about 1 nM to about 10 μM.

### Claim 11 (depends on 1, 5, 10)

The method of claim 1, 5 or 10, wherein the lanthanide binding tag has the sequence:
T0-X1-X2-X3-X4-X5-X6-X7-X8-XH-X9-X10-X11-X12-X13-T14
where T0 and T14 are each independently absent or are an amino acid or peptide,
X1, X3, and X5 are each independently an amino acid with a metal binding side chain,
X7 is an amino acid with a fluorophore-containing side chain, and
XH is absent or is an amino acid or dipeptide,
X2, X4, X6, X8, X9, X10, X11, X12, and X13 are each independently an amino acid.

### Claim 12 (depends on 11)

The lanthanide-binding peptide of claim 11, which binds a lanthanide ion with an affinity (KD) in the μM range.

### Claim 13 (depends on 12)

The lanthanide-binding peptide of claim 12, which binds a lanthanide ion with a KD in the nM range.

### Claim 14 (depends on 13)

The lanthanide-binding peptide of claim 13, which binds a lanthanide ion with a KD in the pM range.

### Claim 15 (depends on 11)

The lanthanide-binding peptide of claim 11, which binds La3+, Eu3+, Sm3+, Gd3+, or Tb3+.

### Claim 16 (depends on 16)

A lanthanide binding peptide comprising an amino acid sequence:
T0-X1-X2-X3-X4-X5-Gly6-Trp7-X8-XH-Glu9-X10-X11-Glu12-Leu 13-T14
where T0 and T14 are each independently absent, an amino acid or peptide;
X1 is Asp, Asn, Ser, or Glu,
X2 is Trp, Tyr, Phe, Gln, Ile or Lys,
X3 is Asp, Asn, Ser, or Glu,
X4 is Trp, Tyr, Ala, Gln, Ile or Lys,
X5 is Asp, Asn, Ser, or Glu,
X8 is Trp, Tyr, Phe, Gln, Ile, Lys or Arg,
XH is absent or is a glycine,
X10 is Trp, Tyr, Glu, Asp, Lys or Phe, and
X11 is Trp, Tyr, Glu, Asp, Lys or Leu;
wherein the peptide contains 14-30 amino acid residues.
The lanthanide-binding peptide of claim 16, wherein T0 and T14 each are independently a peptide containing a cysteine residue.

### Claim 17 (depends on 16)

A fusion protein comprising a protein and the lanthanide binding peptide of claim 16.

### Claim 18 (depends on 18)

A complex comprising the fusion protein of claim 18 and a lanthanide ion.

### Claim 19 (depends on 16)

A polynucleotide encoding the lanthanide-binding peptide of claim 16.

### Claim 20 (depends on 18)

A polynucleotide encoding the fusion protein of claim 18.

### Claim 21 (depends on 20)

A vector comprising the polynucleotide of claim 20 operably linked to a promoter.

### Claim 22 (depends on 21)

A vector comprising the polynucleotide of claim 21 operably linked to a promoter.
